阿托伐他汀联合依折麦布治疗动脉粥样硬化性非闭塞性肠系膜缺血的临床效果

Abstract
Figure/Table
References (20)
Related Citation (9)

Download: PDF (698 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Atorvastatin combined with Ezetimibe in the treatment of atherosclerotic non occlusive mesenteric ischemia and its effect on the levels of blood lipid, inflammatory factors, vascular endothelial function. Methods One hundred and sixty patients with atherosclerotic non occlusive mesenteric ischemia from May 2015 to May 2017 in the First People's Hospital of Foshan City were selected and divided into observation group and control group according to random number table method, with 80 cases in each group. The control group was treated with Atorvastatin treatment, on basis of which, the observation group was added with Ezetimibe, and 80 healthy volunteers matched with the other two groups in age and sex were selected as health group. The blood lipid level, inflammation indices, vascular endothelial function of the three groups were compared and analyzed after treatment for 8 weeks. Results Before treatment, the levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) in the observation group and the control group were higher than those in the healthy group (P ＜ 0.05), and the level of high density lipoprotein cholesterol (HDL-C) was lower than that of the healthy group. There was no significant difference between the observation group and the control group (P ＞ 0.05). The levels of TC, LDL-C and TG in the observation group and the control group decreased significantly after treatment. The observation group was significantly lower than the control group (P ＜ 0.05) and close to the level of the healthy group. The levels of HDL-C in the observation group and the control group were higher than those before treatment, and the increase of the observation group was more obvious, the difference was statistically significant (P ＜ 0.05). Before treatment, the levels of hypersensitivity C reaction protein (hs-CRP) and metalloproteinase -9 (MMP-9) in the observation group and the control group were higher than those in the healthy group (P ＜ 0.05). There was no significant difference in the levels of hs-CRP and MMP-9 between the observation group and the control group (P ＞ 0.05). The levels of hs-CRP and MMP-9 in the observation group and the control group were lower than those before treatment, and the level of the observation group was significantly lower than that of the control group, which was significantly lower than the control group, the difference was statistically significant (P ＜ 0.05). Before treatment, the levels of NO and FMD in the observation group and the control group were lower than those in the healthy group(P ＜ 0.05). There were no significant differences in the levels of nitric oxide (NO) and vascular endothelial function (FMD) between the observation group and the control group (P ＞ 0.05). Compared with those before treatment, the levels of NO and FMD in the observation group and the control group were significantly increased, and the control group increased more obviously, the difference was statistically significant (P ＜ 0.05). After treatment, there were no significant differences in blood lipid level, inflammatory markers and vascular endothelial function between the observation group and the healthy group (P ＞ 0.05). Conclusion Atorvastatin combined with Ezemab can reduce the levels of blood lipid, inflammatory factors and improve vascular endothelial function.

Key words： Atorvastatin Ezetimibe Mesenteric ischemia High sensitivity C reactive protein Metalloproteinase-9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Zhensheng1 QIU Xiaolei1 CHEN Yingyu2 CAI Weibiao3 LIU Shaohui4▲

Cite this article:

YANG Zhensheng1 QIU Xiaolei1 CHEN Yingyu2 CAI Weibiao3 LIU Shaohui4▲. Clinical effect of Atorvastatin combined with Ezetimibe in the treatment of atherosclerotic non occlusive mesenteric ischemia[J]. 中国医药导报, 2018, 15(17): 127-130.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I17/127

[1] 郝东侠，于容至.急性肠系膜缺血性疾病的临床诊治[J].中国临床医生杂志，2018，46（1）：3-6.
[2] 蒋晓发.不同剂量瑞舒伐他汀对老年冠心病合并高脂血症患者的疗效分析[J].国际老年医学杂志，2017，38（3）：108-111.
[3] 容春莉，姚文静，杨倩，等.阿托伐他汀钙联合依折麦布治疗冠状动脉粥样硬化并高脂血症的临床疗效[J].山东大学学报，2015，53（11）：46-49.
[4] 中华医学会老年医学分会，《中华老年医学杂志》编辑委员会.老年人缺血性肠病诊治中国专家建议（2011）[J].中华老年医学杂志，2011，30（1）：1-6.
[5] 杨振声，邱小蕾，钟嘉荣，等.CYP2C19基因多态性对氯吡格雷治疗非闭塞性肠系膜缺血的疗效影响[J].检验医学与临床，2017，14（20）：3073-3078.
[6] Saedon M，Saratzis A，Karim A，et al. Endovascular versus surgical revascularization for the management of chronic mesenteric ischemia [J].Vasc Endovascular Surg，2015，49（1/2）：37-44.
[7] 袁凤仪，吴本俨.急性肠系膜缺血196例临床特点分析[J].中华老年多器官疾病杂志，2016，15（4）：260-264.
[8] 闫静，杨昆，甘华田，等.老年人急性肠系膜缺血的临床特征[J].中华老年医学杂志，2016，35（2）：190-194.
[9] 刘建勇，张维康.急性肠系膜缺血102例诊治分析[J].临床外科杂志，2017，25（9）：665-667.
[10] 付婷婷，王炳元.缺血性肠病研究进展[J].中国临床医生杂志，2016，44（12）：12-16.
[11] Nakashima K，Ishimaru H，Fujimoto T，et al. Diagnostic performance of CT findings for bowel ischemia and necrosis in closed-loop small-bowel obstruction [J]. Abdom Imag，2015，40（5）：1097-1103.
[12] 中国胆固醇教育计划专家委员会，中国医师协会心血管内科医师分会，中国老年学学会心脑血管病专业委员会.选择性胆固醇吸收抑制剂临床应用中国专家共识（2015）[J].中华心血管病杂志，2015，43（5）：394-398.
[13] 王焕兵.阿托伐他汀联合依折麦布对老年高血压患者血脂及炎性因子水平的影响[J].中国医学前沿杂志，2016， 8（8）：136-139.
[14] 陈丽芳，宋晓华，黄于朗.PCI对冠心病患者血清MMP-9、hs-CRP、HMGB1水平的影响及其预后分析[J].中国实验诊断学，2017，21（10）：1714-1717.
[15] 李红艳，芦良花，秦历杰，等.老年冠心病患者中血尿酸对血管内皮功能紊乱的影响[J].中国急救医学，2017， 37（5）：446-449.
[16] 林艾雯，陈竹君.动脉粥样硬化与内皮细胞损伤机制的研究进展[J].岭南心血管病杂志，2015，21（4）：580-582.
[17] 徐花，陆新颖，刘辉，等.血浆Hcy、VE-cadherin、LPA与动脉粥样硬化型急性脑梗死患者颈动脉粥样硬化的关系[J].脑与神经疾病杂志，2018，12（2）：95-99.
[18] 王晓艳，王留义，何姗姗，等.冠状动脉硬化性心脏病患者高密度脂蛋白胆固醇水平及冠状动脉病变程度瘀血管内皮功能的相关性研究[J].中国医药，2017，12（2）：182-186.
[19] 付建平，袁兰所，牟丽娜，等.依折麦布对高迁移率族蛋白1诱导血管内皮细胞激活的影响机制研究[J].北华大学学报：自然科学版，2017，18（1）：46-49.
[20] 王宇，赵姗姗，郑玉敏，等.红花黄色素联合阿加曲班治疗急性脑梗死的疗效及对血清IL-8、ET-1、NO水平和血液流变学的影响[J].中西医结合心脑血管病杂志，2018，11（1）：86-89.